billHR785Event Thursday, April 2, 2026Analyzed

Representing our Seniors at VA Act of 2026

Neutral

Summary

H.R. 785 is a narrow procedural bill that adds one seat to an advisory committee within the VA. It authorizes no spending and creates no new programs. Market impact is negligible for all publicly traded companies.

See which stocks are affected

Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.

Already have an account? Log in

Key Takeaways

  • 1.H.R. 785 is organizational only; it adds one seat to a VA advisory committee.
  • 2.No funding is authorized or appropriated by this bill.
  • 3.No publicly traded companies are affected by this legislation.

Market Implications

There are no market implications from H.R. 785. It does not touch any sector's revenue, costs, or regulatory environment. Retail investors should not make portfolio decisions based on this bill.

Full Analysis

H.R. 785, the Representing our Seniors at VA Act of 2026, was introduced on January 28, 2025 by Representative Kiggans (R-VA-2) and placed on the Union Calendar on April 2, 2026. The bill amends 38 U.S.C. §7315(a) to add one representative from the National Association of State Veterans Homes (NASVH) to the Geriatrics and Gerontology Advisory Committee within the VA. The amendment requires that appointee hold a professional license in nursing home administration and that the Under Secretary for Health consult with the NASVH president on association matters.

The bill contains no authorization of appropriations — it is purely organizational. No federal dollars are allocated, no procurement programs created, no tax credits established. The direct effect is limited to adding one voting seat to an existing advisory body.

Because this bill creates no revenue streams, cost changes, or regulatory burdens for any publicly traded company, there are no identifiable market winners or losers. The affected party is the federal government (VA) — not any private sector entity. Causal chains from this legislation to corporate financial performance do not exist.

The bill has completed committee action and been reported with amendments, but has not passed the House floor. Remaining steps: House floor vote, Senate consideration (no companion bill introduced), and Presidential signature. Given the bill's narrow scope and absence of spending or regulatory impact, further legislative progress will have no material effect on public markets.

Key Legislators

Rep. Kiggans, Jennifer A. [R-VA-2]

Related Presidential Actions

Executive orders & memoranda affecting the same sectors or companies

Exec OrderJun 3, 2026

Implementing Schedule Policy/Career in the Excepted Service

This executive order expands the Schedule Policy/Career excepted service category, transferring certain federal positions from competitive service to at-will employment to facilitate removal for poor performance or misconduct. It directs agency heads to petition for reclassification of policy-influencing roles, mandates performance bonus pools for these employees, and amends civil service rules to exempt them from standard adverse action procedures.

Exec OrderMay 29, 2026

Realigning United States Core Childhood Vaccine Recommendations with Best Practices from Peer, Developed Countries

This executive order directs the CDC and ACIP to review and potentially update the U.S. childhood vaccine schedule to align with recommendations from peer developed countries, which recommend fewer vaccines. It maintains insurance coverage for all currently available vaccines without cost sharing and emphasizes protecting religious liberty and parental authority.

Exec OrderApr 30, 2026

Promoting Efficiency, Accountability, and Performance in Federal Contracting

This executive order mandates that federal agencies default to using fixed-price contracts for procurement, shifting away from cost-reimbursement models. It requires written justification and senior-level approval for any non-fixed-price contract over certain dollar thresholds (e.g., $10M for most agencies, $100M for the Department of War), and directs agencies to review and renegotiate their 10 largest non-fixed-price contracts within 90 days. The order also tasks OMB with implementation guidance and the Federal Acquisition Regulatory Council with proposing regulatory amendments within 120 days.